- Home
- ITRG vs CMRX Comparison
ITRG vs CMRX Comparison
Compare ITRG & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- CMRX
- Stock Information
- Founded
- ITRG 1997
- CMRX 2000
- Country
- ITRG Canada
- CMRX United States
- Employees
- ITRG N/A
- CMRX N/A
- Industry
- ITRG Precious Metals
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ITRG Basic Materials
- CMRX Health Care
- Exchange
- ITRG Nasdaq
- CMRX Nasdaq
- Market Cap
- ITRG 84.2M
- CMRX 77.0M
- IPO Year
- ITRG N/A
- CMRX 2013
- Fundamental
- Price
- ITRG $1.20
- CMRX $0.93
- Analyst Decision
- ITRG Strong Buy
- CMRX Strong Buy
- Analyst Count
- ITRG 1
- CMRX 1
- Target Price
- ITRG $3.75
- CMRX $11.00
- AVG Volume (30 Days)
- ITRG 259.4K
- CMRX 119.4K
- Earning Date
- ITRG 11-12-2024
- CMRX 11-08-2024
- Dividend Yield
- ITRG N/A
- CMRX N/A
- EPS Growth
- ITRG N/A
- CMRX N/A
- EPS
- ITRG N/A
- CMRX N/A
- Revenue
- ITRG N/A
- CMRX $144,000.00
- Revenue This Year
- ITRG N/A
- CMRX $3,040.12
- Revenue Next Year
- ITRG $360.53
- CMRX N/A
- P/E Ratio
- ITRG N/A
- CMRX N/A
- Revenue Growth
- ITRG N/A
- CMRX N/A
- 52 Week Low
- ITRG $0.64
- CMRX $0.75
- 52 Week High
- ITRG $1.28
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- ITRG 66.49
- CMRX 60.78
- Support Level
- ITRG $0.95
- CMRX $0.80
- Resistance Level
- ITRG $1.28
- CMRX $0.98
- Average True Range (ATR)
- ITRG 0.07
- CMRX 0.05
- MACD
- ITRG 0.01
- CMRX 0.01
- Stochastic Oscillator
- ITRG 77.27
- CMRX 83.33
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of highly prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.